<DOC>
	<DOC>NCT00749788</DOC>
	<brief_summary>The purpose of this study is to determine the effect of JTT-302 on the increase of High Density Lipoprotein-Cholesterol (HDL-C) levels when administered daily for four weeks in subjects with low HDL-C levels.</brief_summary>
	<brief_title>Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Subjects with a Body Mass Index (BMI)≤ 35 kg/m2 Subjects with the following lipid parameters at Visit 1 (screening visit) and Visit 3 (diet stabilization period): HDLC ≤ 40 mg/dL (Men) and ≤ 50 mg/dL (Women) TG ≤ 500 mg/dL LDLC ≤ 190 mg/dL Subjects who are generally healthy as determined by prestudy medical history, physical examination, vital signs and 12lead ECG Females who are pregnant or breastfeeding AST, ALT or total bilirubin ≥ 2.0 x ULN at Visit 1 (screening visit) or Visit 3 (diet stabilization period) Serum thyroid stimulating hormone (TSH) and levothyroxine (T4) outside of the central laboratory reference range at the screening visit Medical history of diabetes mellitus or two fasting serum glucose measurements &gt; 126 mg/dL at the screening visit Subjects with hypertension, or two blood pressure measurements ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic at the screening visit History of drug or alcohol abuse within 12 months of the screening visit Use of medications defined in the protocol within sixweeks prior to the screening visit and throughout the study Use of Cytochrome P450 3A4 inducers or inhibitors, as defined in the protocol within four weeks of the screening visit and throughout the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>